Holen Sie sich die Stockscreener-App
5.08
4.51%
-0.24
Vorhandelsmarkt:
5.60
0.52
+10.24%
Schlusskurs vom Vortag:
$5.32
Offen:
$5.34
24-Stunden-Volumen:
418.64K
Relative Volume:
0.42
Marktkapitalisierung:
$403.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.87M
KGV:
-2.8066
EPS:
-1.81
Netto-Cashflow:
$-109.90M
1W Leistung:
-10.41%
1M Leistung:
+8.32%
6M Leistung:
-50.49%
1J Leistung:
-46.53%
1-Tages-Spanne:
$5.04
$5.59
1-Wochen-Bereich:
$4.52
$5.83
52-Wochen-Spanne:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
5.08 | 403.07M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Dimensional Fund Advisors LP Acquires 103,237 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Oppenheimer Issues Pessimistic Forecast for ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - ADVFN
ORIC Pharmaceuticals' (ORIC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Balyasny Asset Management L.P. Purchases 424,194 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
ORIC Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Wedbush Analysts Increase Earnings Estimates for ORIC - MarketBeat
ORIC Pharmaceuticals (ORIC) Receives Increased Price Target from H.C. Wainwright | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (ORIC) Price Target Raised by Analyst | ORIC Stock News - GuruFocus
Wedbush Boosts Earnings Estimates for ORIC Pharmaceuticals - Defense World
Price T Rowe Associates Inc. MD Has $10.45 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Schonfeld Strategic Advisors LLC Takes $5.85 Million Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
1,732,571 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Bought by Boxer Capital Management LLC - MarketBeat
Ratio Review: Analyzing ORIC Pharmaceuticals Inc (ORIC)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
MetLife Investment Management LLC Has $336,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wells Fargo & Company MN - Defense World
ORIC Pharmaceuticals Reports Q1 2025 Progress and Plans - TipRanks
ORIC Pharmaceuticals (ORIC) Target Price Lowered by Oppenheimer | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (ORIC) Receives Reiterated "Overweight" Rat - GuruFocus
Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating - marketscreener.com
Oppenheimer Revises Price Target for ORIC Following Quarterly Re - GuruFocus
Oppenheimer Revises Price Target for ORIC Following Quarterly Results | ORIC Stock News - GuruFocus
Barclays PLC Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reaffirmed at HC Wainwright - Defense World
ORIC Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS Misses Estimate at -0.51, Revenue Remains at $0 Million - GuruFocus
Oric Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oric Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J Partnership, Reports 5 Clinical Readouts Coming in Cancer Drug Pipeline - Stock Titan
Invesco Ltd. Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (ORIC) Rating Reiterated at HC Wainwright & Co. | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
(ORIC) Long Term Investment Analysis - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
Oncology Biotech ORIC Issues Major Equity Package: 32,400 Options Plus RSUs for New Talent - Stock Titan
An analyst sees good growth prospects for ORIC Pharmaceuticals Inc (ORIC) - Sete News
Market Watch: ORIC Pharmaceuticals Inc (ORIC)’s Noteworthy Drop, Closing at 5.57 - DWinneX
Is ORIC Pharmaceuticals Inc (ORIC) worth investing in despite its overvalued state? - uspostnews.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Legal & General Group Plc - Defense World
ORIC Pharmaceuticals Inc’s Shares Reel: -51.58% Quarterly Revenue Decline Amid 401.98M Market Cap - investchronicle.com
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
79,900 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Acquired by Natixis - MarketBeat
ORIC-944 shows promise in prostate cancer treatment - Investing.com
ORIC Pharmaceuticals Highlights Promising Preclinical Data on OR - GuruFocus
ORIC® Pharmaceuticals Presents Preclinical Data to Support the P - GuruFocus
ORIC-944 shows promise in prostate cancer treatment By Investing.com - Investing.com South Africa
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):